

10 T.W.  
 Application No. 13/535268  
 Responsive to the office action dated December 1, 2009

RECEIVED  
 CENTRAL FAX CENTER


APR 01 2010

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A compound represented by formula (I):



wherein R is naphthyl optionally substituted with a halogen atom or indolyl optionally substituted with a halogen atom, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents -CO-, ring A represents an optionally substituted piperidine ring, Z<sup>1</sup> and Z<sup>3</sup> independently represent a bond, Z<sup>2</sup> represents -N(R<sup>1</sup>)- (R<sup>1</sup> represents an optionally substituted hydrocarbon group, an optionally substituted acyl group, an optionally esterified carboxyl group, or an optionally substituted carbamoyl group), ring B represents an optionally substituted imidazole ring, wherein a substituent that the optionally substituted imidazole ring represented by ring B may have may be taken together with R<sup>1</sup> to form an optionally substituted ring, and a represents 2, or a pharmaceutically acceptable salt thereof.

2-4. (Cancelled)

5. (Original) The compound according to claim 1, wherein W is a bond.

6. (Original) The compound according to claim 1, wherein X is an optionally substituted divalent linear hydrocarbon group.


7-8. (Cancelled)

IOT.W


Application No. 15/535268

Responsive to the office action dated December 1, 2009

9. (Original) The compound according to claim 1, wherein the formula:




is the formula:



wherein  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$  and  $R^{13}$  independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted acyl group, an optionally esterified carboxyl group, an optionally substituted carbamoyl group or an optionally substituted amino group, or  $R^2$  and  $R^3$ ,  $R^5$  and  $R^6$ ,  $R^6$  and  $R^7$ ,  $R^8$  and  $R^9$ ,  $R^9$  and  $R^{10}$ , or  $R^{11}$  and  $R^{12}$  may be taken together to form an optionally substituted ring.

10-12. (Cancelled)

13. (Previously Presented) The compound according to claim 1, wherein the formula (I) is the formula (Ia):



wherein ring  $B'$  represents an optionally further substituted imidazole ring,  $Z^{2a}$  represents N,  $Z^4$  represents an optionally substituted divalent linear hydrocarbon group, and other symbols are as defined in claim 1.

157.1

Application No. 437535268


Responsive to the office action dated December 1, 2009

14. (Cancelled)

15. (Currently Amended) The compound ~~as recited according~~ according to claim 13, wherein ~~Z<sup>2</sup> and Z<sup>4</sup> are independently~~ is a divalent linear hydrocarbon group optionally substituted with an oxo group.

16-17. (Cancelled)

18. (Currently Amended) The compound according to claim 1, wherein the formula (I) is the formula (Id):



wherein Z<sup>2a</sup> represents N, Z<sup>4</sup> represents an optionally substituted divalent linear hydrocarbon group, R<sup>18</sup> and R<sup>19</sup> independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted acyl group, an optionally esterified carboxyl group, an optionally substituted carbamoyl group, or an optionally substituted amino group, and other symbols are as defined in claim 1 ~~or 13~~.

19. (Cancelled)

20. (Currently Amended) A compound selected from the group consisting of 2-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,

IOTW.

Application No. 157535268

Responsive to the office action dated December 1, 2009

2-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-5,7-dimethyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,  
 2-(1-{3-[(5-chloro-1H-indol-2-yl)sulfonyl]propanoyl}-4-piperidinyl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,  
 2-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-5-(hydroxymethyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,  
 2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-5-(hydroxymethyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,  
 [2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl 1-acetylpiperidine-4-carboxylate,  
 [2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl 3-(2-oxo-1-pyrrolidinyl)propionate,  
 [2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl (2-oxo-1-pyrrolidinyl)acetate,  
 [2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl 4-(acetylamino)butanoate, and  
 2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-5,7-dimethyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one or a pharmaceutically acceptable salt thereof.

21. (Currently Amended) A pharmaceutical preparation which comprises the compound according to claim 1 along with a pharmaceutically acceptable carrier.

22. (Currently Amended) The pharmaceutical preparation according to claim 21, which includes the compound in an amount providing has an anticoagulant effect.

I.O.T.W.

Application No. ~~45~~535268

Responsive to the office action dated December 1, 2009

23. (Currently Amended) The pharmaceutical preparation according to claim 21, which includes the compound in an amount effective for inhibiting ~~inhibits an activated~~ blood coagulation factor X.

24. (Currently Amended) The pharmaceutical preparation according to claim 21, which includes the compound in an amount effective for ~~has an effect on~~ preventing or treating myocardial infarction, cerebral infarction, deep venous thrombosis, pulmonary thromboembolism or arterioscleroticobliterans.

25. (Currently Amended) The pharmaceutical preparation according to claim 21, which includes the compound in an amount effective for ~~has an effect on~~ preventing or treating economy class syndrome, thromboembolism during or after an operation, or a secondary onset of deep venous thrombosis.

26 - 37. (Cancelled)

38. (New) 2-(1-{3-[(6-Chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one or a pharmaceutically acceptable salt thereof.